Reviews/Rheumatoid Arthritis Targeted Therapy/JAK inhibitors match biologic disease-modifying antirheumatic drugs for remission in rheumatoid arthritis, given orally
JAK Inhibitors · RA-JAK-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across this corpus, oral JAK inhibitors repeatedly match or beat biologic drugs on how many patients reach low disease activity or remission in people whose methotrexate is not enough. Two randomised trials placed an oral JAK inhibitor alongside an injected biologic and found the JAK inhibitor's response rates sat in or above the biologic's range [23][8], and three real-world studies found JAK inhibitor remission at least as good as biologics [1][3][5]. Trials in the exact methotrexate-inadequate group confirm the JAK inhibitor clearly beats placebo on both ACR50 and DAS28 remission [9][10]. All the JAK inhibitors studied are taken by mouth, so oral delivery is not in doubt. The panel stopped short of the top tier because none of the trials was actually designed and sized to prove the JAK inhibitor is statistically as good as a biologic, and the real-world studies mix in patients who are not strictly methotrexate-inadequate.
Two randomised trials in DMARD-inadequate responders carried an oral JAK inhibitor against a biologic reference arm: tofacitinib versus adalimumab, with ACR20 at week 12 of 59.2% for tofacitinib 5 mg twice daily and 35.9% for adalimumab [23], and peficitinib versus open-label etanercept [8]. Three real-world comparisons show JAK inhibitor remission meeting or exceeding biologics, including DAS28CRP(3) remission of 75.0% for upadacitinib versus 59.5% for TNF inhibitors [1], higher Boolean remission on JAK-STAT inhibitors [3], and the highest CDAI remission rate for the JAK inhibitor group after IPTW [5]. In the strict methotrexate-inadequate population, placebo-controlled trials confirm the ACR50 and DAS28-remission signal, with baricitinib achieving ACR20 of 76% versus 41% for placebo plus significant ACR50 and DAS28 remission [10], and ABT-494 showing significantly higher ACR50 and DAS28-CRP responses than placebo [9]. Every JAK inhibitor in the corpus is orally administered [8][23][10]. The contested point: The division is whether 'comparable to biologics' is demonstrated or inferred: the only head-to-head trials used biologic arms that were reference or open-label and not powered for non-inferiority [23][8], so comparability is read across arms rather than formally tested. The ACR50 half of the claim is never tested directly against a biologic at all — trials report ACR50 only versus placebo [9][10].
All 25 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Rheumatoid Arthritis Targeted Therapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only head-to-head RCTs ([23] adalimumab, [8] etanercept) used open-label/reference bDMARD arms not powered for non-inferiority; 'comparable' is a numerical inference across arms, not demonstrated statistical equivalence.
ACR50 comparability specifically to bDMARDs is never directly tested — RCTs report ACR50 only versus placebo; the ACR50 half of the claim rests on cross-arm eyeballing.
Where it remains uncertain. The comparison rests on biologic arms not powered for non-inferiority [23][8] and confounded observational cohorts [1][3][5], and ACR50 comparability to biologics is never directly tested [9][10].
Aleatory
Response rates vary across JAK inhibitors and doses (e.g. ABT-494 ACR20 62-80% across doses [9]), adding sampling variability to any pooled 'comparable' judgment.
Epistemic
No trial in the corpus was sized to test statistical equivalence of a JAK inhibitor to a biologic in MTX-IR patients [23][8].
Inferential
Comparability is inferred by reading JAK inhibitor response rates against a non-inferiority-unpowered reference arm rather than a prespecified contrast [23][8].
The load-bearing papers from a corpus of 25, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Real-world DAS28 remission for JAKi (UPA) meets or exceeds TNFi bDMARD
“DAS28CRP(3) remission rates were greater at 3 months for UPA than other JAKis (75.0% versus 61.5%) and TNFis (72.7% versus 59.5%).”
Panel auditInternal validity: medium · scope of inference: Real-world RA patients initiating UPA, other JAKis, or TNFis in Australia 2020-2023; DAS28-CRP remission at 3 months.Key limitations: retrospective non-randomised · not MTX-IR-defined population · no significance test on remission comparison · 3-month window
Direct biologic-vs-JAKi cohort with JAKi achieving higher Boolean remission despite heavier prior treatment
“group I (80 patients) treated with biologic agents, and group II (50 patients) treated with JAKi”
Panel auditInternal validity: low · scope of inference: 130 severe active RA patients at one Polish centre, SDAI/Boolean remission.Key limitations: baseline imbalance in prior treatments · not randomised · SDAI/Boolean not ACR50/DAS28 remission · single centre
JAKi remission meets or exceeds TNFi/IL-6i/CTLA4-Ig bDMARDs in a b/tsDMARD-experienced registry
“At 24 weeks, the JAKi group showed the greatest improvement in CDAI and the highest CDAI remission rate.”
Panel auditInternal validity: medium · scope of inference: 687 RA patients unresponsive to first-line b/tsDMARDs, CDAI remission at 24 weeks.Key limitations: second-line not MTX-IR population · CDAI not ACR50/DAS28 remission · non-randomised registry · no significance reported
No biologic comparator is present, so comparability to biologics cannot be assessed.
Panel auditInternal validity: high · scope of inference: 301 MTX-IR RA patients, ACR50 and DAS28<2.6 remission vs placebo at week 12.Key limitations: no biologic comparator · placebo-controlled only · conference abstract
4 of 25 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Evidence consistently supports comparability and oral delivery, but the strict statistical comparability of ACR50 to bDMARDs in the exact population is inferred rather than formally demonstrated.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Powered non-inferiority head-to-head for ACR50. No trial tests statistical equivalence of a JAK inhibitor to a biologic on ACR50 in the exact MTX-IR population; the claim's ACR50 half rests on cross-arm inference [23][8][9]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, double-blind non-inferiority trial in strictly methotrexate-inadequate RA with a prespecified ACR50 margin against an active biologic comparator.
Open question: Is a JAK inhibitor statistically non-inferior to a biologic on ACR50 in strictly methotrexate-inadequate responders? Why it is still open: Head-to-head trials report ACR50 only against placebo and used biologic arms not powered for non-inferiority [23][8][9][10].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19